VECTOR CORE FACILITY

矢量核心设施（VCF）已经并将继续作为重要的共享设施， UPCI研究人员通过提供数百种病毒和非病毒载体和试剂， 成员，特别是用于癌症基因治疗。虽然超过50%的使用， 共享设施是由UPCI成员提供的，请求CCSG的支持仅占总数的约15 设施的预算。VCF在UPCI框架内作为动态资源发挥作用， 开发新型载体并提供最先进的病毒和非病毒载体技术。主要 VCF的重点是利用腺病毒和逆转录病毒载体进行基因转导。 该设施也有能力生产腺相关病毒和DNA质粒的基因 交付.除了载体，该设施还提供细胞系，病毒，包装线，质粒， 议定书，以及在使用病毒和非病毒载体方面向个人提供技术援助和培训 用于基因转移。为了应对研究需求的增长，在过去的一年里，VCF扩大了 其重点是包括用于表达shRNA和cDNA的慢病毒载体，以帮助基因发现的研究， 药物开发和靶点验证，并向UPCI成员提供这些专业知识和试剂 参与了慢病毒载体的基础科学研究。目前，VCF提供的服务包括： 低滴度HIV和FIV慢病毒，制备用于荧光蛋白表达和shRNA的储备病毒 从人和小鼠基因特异性文库中表达，设计和开发用于 用于基于细胞的研究和转基因小鼠生产、细胞转导和 表征（稳定细胞系的开发和qRT-PCR分析）和慢病毒滴度， 测试复制能力。 矢量核心基金的具体目标是： 1.为UPCI研究者提供表达shRNA或特定基因的病毒和非病毒载体， 感兴趣并且对于他们提出的实验最合适和有效的。 2.开发改进的病毒和非病毒载体，以更高的和/或更有效的基因转移。 调控基因表达。 3.协助开发新的、最先进的高效基因递送方法。 4.为基因治疗项目提供技术援助和协议，利用病毒和非病毒 基因传递系统

The Vector Core Facility (VCF) has served, and will continue to serve, as an important shared facility for UPCI researchers by providing many hundreds of viral and non-viral vectors and reagents to UPCI members, particularly for use in cancer gene therapy. Although greater than 50% of the usage of this shared facility is by UPCI members, requested CCSG support is only approximately 15% of the total budget of the facility. The VCF functions within the framework of the UPCI as a dynamic resource that develops novel vectors and provides state-of-the-art viral and non-viral vector technology. The major emphasis of the VCF has been on the utilization of adenoviral and retroviral vectors for gene transduction. This facility also has the capability to produce adeno-associated viruses and DNA plasmids for gene delivery. In addition to vectors, the facility also provides cell lines, viruses, packaging lines, plasmids, and protocols, as well as technical assistance and training to individuals in the use of viral and non-viral vectors for gene transfer. In response to a growth in research demand, over the last year the VCF has expanded its focus to include lentiviral vectors for expression of shRNA and cDNA to aid in studies of gene-discovery, drug development and target validation, and to provide this expertise and reagents to UPCI members involved in basic science research using lentiviral vectors. Currently the VCF provides include high- and low-titer HIV and FIV lentivirus, preparation of stock viruses for fluorescent protein expression and shRNA expression from a library specific to human and mouse genes, design and development of lentiviruses for cDNA expression for cell-based studies and transgenic mouse production, cell transduction & characterization (development of stable cell lines and analysis by qRT-PCR) and lentiviral titering and testing for replication competence. The specific aims of the Vector Core Facility are to: 1. Provide UPCI investigators with viral and non-viral vectors that express shRNA or the specific gene of interest and that are most appropriate and efficacious for their proposed experiments. 2. Develop improved viral and non-viral vectors for more efficient gene transfer with higher and/or regulated gene expression. 3. Assist in the development of new, state-of-the-art methods for efficient gene delivery. 4. Provide technical assistance and protocols for gene therapy projects, making use of viral and non-viral gene delivery systems.